ebook Munafa Stock Market Course + Intraday & FNO calls  

       

NVO announcements Novo Nordisk A/s announcements and dividends declared USA

Novo Nordisk A/s Complete list of announcements declared & dividend announcements by Novo Nordisk A/s NVO

Novo Nordisk A/s NVO listed on USA and deals in Health Care Major Pharmaceuticals

Announcements and dividends declared by Novo Nordisk A/s NVO

Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakers
India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. This is impacting Eli Lilly's drug sales. The market is expected to grow significantly. Indian drugmakers are launchi
Announcement as on 09 April 2026

Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk
The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Novo Nordisk in the GLP-1 medicine market. Foundayo is an oral medication offering a new option for weight management. L
Announcement as on 02 April 2026

Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expires
Natco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the innovator's drug. The company aims to make this treatment more accessible to patients across India. Other pharmaceutical
Announcement as on 20 March 2026

FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Announcement as on 20 March 2026

Novo Nordisk says new weight-loss drug not as potent as Eli Lilly's; stock sinks

Announcement as on 23 February 2026

Announcements by Novo Nordisk A/s first page | Next page |

NVO Novo Nordisk A/s current price & indicator signals

Moving Averages for Novo Nordisk A/s

  • 5Day Average: 39.75
  • 12Day Average: 39.44
  • 20Day Average: 38.3
  • 50Day Average: 39.62
  • 100Day Average: 46.44
  • 150Day Average: 48.66
  • 200Day Average: 51.02

NVO Indicators & signals

Indicator MACD (12,26,9)

39.36, 39.15, -0.2
Indicator MACD is in positive zone

Indicator ADX (14)

13.92, 31.91, 24.11
Indicator ADX is indicating that momentum is weak.
Indicator ADX is showing that momentum is towards buying

Indicator RSI (14)

Current RSI is: 57
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of NVO Novo Nordisk A/s are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
24 Fri Apr 2026 41.17 38.22 to 41.23 6.88% 1.4 times
23 Thu Apr 2026 38.52 38.02 to 39.20 -1.61% 0.84 times
22 Wed Apr 2026 39.15 38.85 to 39.33 -0.68% 1.19 times
21 Tue Apr 2026 39.42 38.70 to 40.20 -2.59% 1.72 times
20 Mon Apr 2026 40.47 39.75 to 40.85 -0.12% 0.55 times
17 Fri Apr 2026 40.52 40.43 to 41.29 -1% 0.9 times
16 Thu Apr 2026 40.93 40.23 to 41.66 0.29% 0.85 times
15 Wed Apr 2026 40.81 39.67 to 40.86 3.79% 1.32 times
14 Tue Apr 2026 39.32 37.91 to 39.78 3.53% 1.13 times
13 Mon Apr 2026 37.98 36.95 to 38.01 1.23% 0.87 times
10 Fri Apr 2026 37.52 37.23 to 38.42 0.19% 0.64 times
09 Thu Apr 2026 37.45 36.82 to 37.65 -0.43% 0.61 times

Videos related to: NVO announcements Novo Nordisk A/s announcements and dividends declared USA

Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra

Hindi Video What Is Needed To Succeed In Stock Markets

NVO announcements Novo Nordisk A/s announcements and dividends declared USA

 

Back to top